ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
DSM says it won't sell its special products business to Arsenal Capital Partners as previously announced. The business, with annual sales of about $150 million, makes benzoic acid and derivatives at a plant in the Netherlands. The sale to Arsenal was announced in March 2008, but a subsequent ruling by the European Commission required Arsenal to sell a benzoic acid plant in Estonia operated by its Velsicol Chemical subsidiary. DSM says the requirement "led to the conclusion that the intended sale is no longer feasible.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter